Company Market Research Report: Enliven Therapeutics

Company Overview

• Name: Enliven Therapeutics

• Mission: To help people with cancer to not only live longer, but live better.

• Founded By: No information is available.

• Key People:

• Sam Kintz, MBA: Co-founder, Chief Executive Officer, and Member of the Board of Directors

• Joe Lyssikatos, PhD: Co-founder, Chief Scientific Officer

• Anish Patel, PharmD: Co-founder and Chief Operating Officer

• Helen Collins, MD: Chief Medical Officer

• Ben Hohl: Chief Financial Officer and Head of Corporate Development

• Galya Blachman, PhD, Esq: Chief Legal Officer and Head of Business Development

• Board of Directors:

• Rich A. Heyman, PhD

• Sam Kintz, MBA

• Rishi Gupta, JD

• Andy Phillips, PhD

• Mika Kakefuda Derynck, MD

• Jake Bauer, MBA

• Rahul Ballal, PhD

• Lori Kunkel, MD

• Scientific Advisors:

• Brian Druker, MD

• Kevin Koch, PhD

• Headquarters: 6200 Lookout Road, Boulder, CO 80301

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Development of small molecule kinase inhibitors focusing on cancer treatment. They are notable for their precision oncology approach improving survival and well-being.

Products

ELVN-001

• Program: BCR-ABL Program

• Description: A potent, highly selective, small molecule kinase inhibitor targeting BCR-ABL gene fusion in chronic myeloid leukemia (CML).

• Key Features:

• Addresses tolerability, safety, resistance, and convenience issues.

• Designed with activity against the T315I mutation.

• Potential complementary option to allosteric BCR-ABL inhibitors.

ELVN-002

• Program: HER2 Program

• Description: Highly selective, CNS penetrant, irreversible HER2 inhibitor targeting HER2 mutations, wild-type HER2 and avoiding EGFR-related toxicities.

• Key Features:

• Improved therapeutic index compared to current therapies.

• Designed for combination therapies.

• Aims to provide an option for patients with brain metastases.

Recent Developments

• New Products Launched: No new products launched.

• New Features:

• Recent positive proof of concept data for ELVN-001's Phase 1 clinical trial in patients with CML.

• Evaluation of ELVN-002 in phase 1 clinical trials for efficacy against HER2-driven malignancies and brain metastases.

• Partnerships: No information is available.

Contact Information

• General & Business Inquiries: info@enliventherapeutics.com

• Investor Inquiries: ir@enliventherapeutics.com

• Media Inquiries: media@enliventherapeutics.com

• Employment Inquiries: hr@enliventherapeutics.com

• LinkedIn: No direct link available.